There is also an urgent need for biomarkers that can predict and measure the response to IPF treatment, and a relatively large number of relevant indicators have emerged for both drugs after treatment, such as CA-125, serum SP-D, KL-6 and CCL18 [50]. Here, CCL18 is linked to idiopathic pulmonary fibrosis.